Ivan Lin

Head of Manufacturing and Head of MSAT & ATS at JW Therapeutics

Speaker

Dr. Ivan Lin, is currently the Head of MSAT & ATS and Head of MAH Manufacturing at JW Therapeutics Co., Ltd. (MAH of Relma-Cel, a commercialised CAR-T cell therapy product approved NMPA). Dr. Lin has over ten years of experience in the cell and gene therapy industry, possessing extensive experience and unique insights in areas such as the establishment and improvement of GMP systems, technology transfer, process qualification and validation, development and life cycle management. At JW Therapeutics, Dr. Lin led the team to transfer Relma-Cel to commercial facility, follow by process validation; completed the biologics marketing authorization application and obtained approval; completed several post-marketing requirements and post-approval supplement for Relma-Cel; and participated in the establishment and operation of Relma-Cel commercialization system. Dr. Lin works closely with regulatory authorities and participated in the preparation of several CGT guidelines.